Moh Tadayyon

Moh has over two decades of experience spanning discovery, pre-clinical and early development, clinical translation and scientific commercial strategy. Moh is a co-founder of Apeikon Therapeutics, a spinout from King’s College London that is developing a novel drug-delivery technology for treatment of solid tumours, including glioblastoma. Moh’s early career was in metabolic disease research where he led multiple programs that delivered several clinical candidates including the now marketed antidiabetic linagliptin.